Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development

被引:0
|
作者
Brenda Gaydos
Keaven M. Anderson
Donald Berry
Nancy Burnham
Christy Chuang-Stein
Jennifer Dudinak
Parvin Fardipour
Paul Gallo
Sam Givens
Roger Lewis
Jeff Maca
José Pinheiro
Yili Pritchett
Michael Krams
机构
[1] Eli Lilly and Co.,
[2] Lilly Corporate Center,undefined
[3] Merck,undefined
[4] Anderson Cancer Center,undefined
[5] GSK,undefined
[6] Pfizer,undefined
[7] Roche,undefined
[8] Wyeth,undefined
[9] Novartis,undefined
[10] Harbor-UCLA Medical Center,undefined
[11] Abbott,undefined
来源
Drug information journal : DIJ / Drug Information Association | 2009年 / 43卷 / 5期
关键词
Adaptive design; Best practices; Flexible design; Implementation; Planning;
D O I
暂无
中图分类号
学科分类号
摘要
This article is a summary of good adaptive practices for the planning and implementation of adaptive designs compiled from experiences gained in the pharmaceutical industry. The target audience is anyone involved in the planning and execution of clinical trials. The first step prior to planning an adaptive design is to assess the appropriateness of its use. Hence, strategic points to consider when assessing if an adaptive design is the right choice for a trial are discussed. In addition, strategic points for consideration at the design and implementation stage are included from operational, regulatory, clinical, and statistical perspectives. Good practices for trial simulation, trial documentation, and data monitoring committees are provided.
引用
收藏
页码:539 / 556
页数:17
相关论文
共 50 条
  • [1] Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development
    Gaydos, Brenda
    Anderson, Keaven M.
    Berry, Donald
    Burnham, Nancy
    Chuang-Stein, Christy
    Dudinak, Jennifer
    Fardipour, Parvin
    Gallo, Paul
    Givens, Sam
    Lewis, Roger
    Maca, Jeff
    Pinheiro, Jose
    Pritchett, Yili
    Krams, Michael
    DRUG INFORMATION JOURNAL, 2009, 43 (05): : 539 - 556
  • [2] Pharmaceutical new product development: why do clinical trials fail?
    Buonansegna, Erika
    Salomo, Soren
    Maier, Anja M.
    Li-Ying, Jason
    R & D MANAGEMENT, 2014, 44 (02) : 189 - 202
  • [3] Good clinical practices in monitoring antihypertensive clinical trials.
    Jett, CM
    AMERICAN JOURNAL OF HYPERTENSION, 1999, 12 (04) : 115A - 115A
  • [4] Certification of Clinical Sites in Good Clinical Practices for the Conduct of Clinical Trials
    Cuevas Perez, Olga Lidia
    Fernandez Ruiz, Diana Rosa
    Diaz Diaz, Jayce
    MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2015, 13 (04): : 478 - 480
  • [5] Operational Differences between Product Development Partnership, Pharmaceutical Industry, and Investigator Initiated Clinical Trials
    Nebie, Eric, I
    van Eeuwijk, Peter
    Sawadogo, Helene N.
    Reus, Elisabeth
    Utzinger, Juerg
    Burri, Christian
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2024, 9 (03)
  • [6] THE CONDUCT OF CLINICAL-TRIALS AND GOOD CLINICAL PRACTICES - THE SPONSORS PERSPECTIVE
    ROBB, EJ
    DAVIS, DD
    FARRINGTON, DO
    JOURNAL OF ANIMAL SCIENCE, 1995, 73 (02) : 614 - 621
  • [7] GOOD PHARMACEUTICAL MANUFACTURING PRACTICES
    LEHIR, A
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1989, 15 (6-7) : 853 - 868
  • [8] The ANRS initiative on clinical trials good clinical practices in resource-limited countries: development of quality indicators
    Hanna, M.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2012, 17 : 12 - 12
  • [9] PECULIARITIES OF APPLICATION OF GOOD CLINICAL PRACTICES IN THERAPEUTIC TRIALS TO GERIATRICS
    PIETTE, F
    THERAPIE, 1991, 46 (01): : 83 - 87
  • [10] CLINICAL AUDIT: DEVELOPMENT OF THE CRITERIA OF GOOD PRACTICES
    Soimakallio, S.
    Alanen, A.
    Jarvinen, H.
    Ahonen, A.
    Ceder, K.
    Lyyra-Laitinen, T.
    Paunio, M.
    Sinervo, T.
    Wigren, T.
    RADIATION PROTECTION DOSIMETRY, 2011, 147 (1-2) : 30 - 33